Predictive Oncology Inc Stock

$1.13+0.00 (+0%)
Updated Jun 20, 2024
POAI Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 8, 2024
Next Dividend

POAI Overview

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how POAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

POAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
POAI is good value based on its book value relative to its share price (1.14x), compared to the US Medical Instruments & Supplies industry average (3.65x)
P/B vs Industry Valuation
POAI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more POAI due diligence checks available for Premium users.

Be the first to know about important POAI news, forecast changes, insider trades & much more!



POAI fair value

Fair Value of POAI stock based on Discounted Cash Flow (DCF)
Fair Value
Overvalued by
POAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

POAI price to earnings (PE)

For valuing profitable companies with steady earnings

POAI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
POAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

POAI's financial health

Profit margin

Net Income
Profit Margin
POAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
POAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
POAI's short-term assets ($6.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
POAI's short-term assets ($6.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
POAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
POAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

POAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

POAI vs Medical Stocks

TickerMarket Cap1d %P/EP/B

Predictive Oncology Stock FAQ

What is Predictive Oncology's quote symbol?

(NASDAQ: POAI) Predictive Oncology trades on the NASDAQ under the ticker symbol POAI. Predictive Oncology stock quotes can also be displayed as NASDAQ: POAI.

If you're new to stock investing, here's how to buy Predictive Oncology stock.

What is the 52 week high and low for Predictive Oncology (NASDAQ: POAI)?

(NASDAQ: POAI) Predictive Oncology's 52-week high was $7.12, and its 52-week low was $1.11. It is currently -84.13% from its 52-week high and 1.8% from its 52-week low.

How much is Predictive Oncology stock worth today?

(NASDAQ: POAI) Predictive Oncology currently has 4,101,776 outstanding shares. With Predictive Oncology stock trading at $1.13 per share, the total value of Predictive Oncology stock (market capitalization) is $4.64M.

Predictive Oncology stock was originally listed at a price of $131,250.00 in May 3, 2010. If you had invested in Predictive Oncology stock at $131,250.00, your return over the last 14 years would have been -100%, for an annualized return of -56.53% (not including any dividends or dividend reinvestments).

How much is Predictive Oncology's stock price per share?

(NASDAQ: POAI) Predictive Oncology stock price per share is $1.13 today (as of Jun 20, 2024).

What is Predictive Oncology's Market Cap?

(NASDAQ: POAI) Predictive Oncology's market cap is $4.64M, as of Jun 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Predictive Oncology's market cap is calculated by multiplying POAI's current stock price of $1.13 by POAI's total outstanding shares of 4,101,776.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.